Glyphic Biotechnologies has filed a notice of an exempt offering of securities to raise $52,917,435.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Glyphic Biotechnologies is raising up to $52,917,435.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Joshua Yang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Glyphic Biotechnologies
We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease.
To learn more about Glyphic Biotechnologies, visit http://glyphic.bio/
Contact:
Joshua Yang, Chief Executive Officer
619-944-9009
https://www.linkedin.com/in/joshuayoungyang/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.